Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer...(t during the treatment. The electronic b...),Health

The study, which began enrolling in April 2007, was performed at 10 clinical sites, including Swedish Cancer Institute; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Rush University Medical Center, Chicago; Little Company of Mary Hospital, Evergreen Park, IL; Wellstar Health System, Marietta, GA; Providence Hospital, Providence, RI; Mills Peninsula Hospital, San Mateo, Calif; Beth Israel Medical Center, New York, NY; White Plains Hospital, White Plains, NY; and Maryland Regional Cancer Center, Silver Spring, MD.

Eligible patients received an accelerated course of radiation treatment delivering 3.4 Gy/fraction twice a day for five days. The primary endpoint of the study was the successful delivery of the prescribed radiation therapy and the secondary endpoint was the collection of adverse device related events. Interim results presented at the ASCO Symposium on 38 patients who completed treatment showed that 25 of these patients had been followed for a minimum of 1 month post-treatment. In this group, the electronic brachytherapy treatment was successfully delivered in every patient for every fraction. The side effects of treatment reported were generally mild, manageable, and expected.

Dr. Mehta will also present further findings from this study at an educational symposium in conjunction with the ASTRO Meeting in Boston on September 22. In addition to Dr Mehta's presentation, the program, titled "Electronic Brachytherapy: Innovation and Conversations" will feature a panel of leading radiation oncologists and breast surgeons discussing new indications for Electronic Brachytherapy, including the treatment of endometrial cancer and intraoperative therapy.

In its treatment of ea
'/>"/>